EXSIGHT ADDS 60% TO FUND 3 INCLUDING A LEADING EYE CARE FOUNDATION
ExSight Ventures, a specialized ophthalmic-focused venture capital firm, is thrilled to announce a significant increase in capital for its most recent dedicated ophthalmology fund. The capital infusion will further fuel the complementary missions of both ExSight and The Glaucoma Foundation to foster innovation, drive advancements, and enhance patient care within the field of ophthalmology, including bringing impactful innovation to glaucoma care. The Glaucoma Foundation is one of the leading not-for-profits dedicated to the study of glaucoma and the search for its cure.
This additional investment will enable ExSight to provide greater support and critical capital to ophthalmic startups. These commitments will drive transformative innovations in the diagnosis and treatment of ophthalmic diseases, including glaucoma.
ExSight’s most recent fund has already made notable investments in cutting-edge technologies and visionary startups that are poised to redefine the landscape of eye care. Among this fund’s investments is Elios Vision, a next-generation glaucoma treatment. The ELIOS procedure is an innovative glaucoma treatment that preserves the trabecular meshwork, is broadly adoptable by surgeons, and does not require an implant. By using excimer laser light technology to create microscopic openings in the trabecular meshwork, ELIOS is designed to facilitate the outflow of aqueous. ELIOS has been CE-marked in Europe and is currently undergoing investigational trials in the United States.
Other select ExSight portfolio companies include:
Novai, developing a novel real-time cellular imaging technology combining a biologic with AI to preserve sight through early detection and treatment.
Horizon Surgical Systems, revolutionizing microsurgery through advancements in robotics, medical imaging, and artificial intelligence.
Re-Vana Therapeutics, a pioneering ocular drug delivery and therapeutic company focused on developing the world’s first sustained-release large molecule biologics to treat serious eye diseases.
Valitor, leveraging its multivalent biopolymer technology to maximize benefits for patients. Valitor is initially focused on improving patient outcomes in ophthalmology and vision-threatening diseases.
These additional capital commitments will provide essential capital to companies enabling greater opportunities for entrepreneurs and innovators to bring their vision-saving ideas to life, with the potential to positively impact millions of patients worldwide.
ExSight Ventures (EV) is a returns-oriented, mission-focused life sciences venture capital firm specializing in early-stage investments in innovative ophthalmic diagnostic and treatment solutions. We created the firm to address the dearth of early-stage funding available to life science companies. We rely on our team’s diverse experiences in venture capital and healthcare in our investment selection process and subsequently, to assist our portfolio companies. EV invests in biotechnology, medical devices, pharmaceuticals, and software solutions with ophthalmic applications.
The Glaucoma Foundation, founded in 1984, is dedicated to improving the lives of people with glaucoma. The Foundation works to encourage and support basic and applied research in glaucoma with a goal of preserving and restoring vision. We strive to be an important resource to help patients, their families, and at-risk individuals to manage their glaucoma through education and outreach.